A Review of Obesity, Insulin Resistance, and the Role of Exercise in Breast Cancer Patients

REFERENCES

• World Health Organization: Noncommunicable Diseases; Cancer; Breast Cancer. Accessed from http://www.emro.who.int/ncd/cancer_breast.htm
   Google Scholar
• American Cancer Society: How Many Women Get Breast Cancer? 2014. Accessed from http://www.cancer.org/Cancer/BreastCancer/OverviewGuide/breast-cancer-overview-key-statistics
   Google Scholar
• Nickels S, Truong T, Hein R, Stevens K, Buck K, et al.: Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors. PLoS Genet 9(3), e1003284, 2013.
   Google Scholar
• Carmichael AR: Obesity and prognosis of breast cancer. Obes Rev 7, 333–340, 2006.
   PubMed Web of Science ®Google Scholar
• Bruning PF, Bonfrer JM, van Noord PA, Hart AA, de Jong-Bakker M, et al.: Insulin resistance and breast-cancer risk. Int J Cancer 52, 511–516, 1992.
   PubMed Web of Science ®Google Scholar
• Caan BJ, Emond JA, Natarajan L, Castillo A, Gunderson EP, et al.: Post-diagnosis weight gain and breast cancer recurrence in women with early stage breast cancer. Breast Cancer Res Treat 99, 47–57, 2006.
   PubMed Web of Science ®Google Scholar
• Kroenke CH, Chen WY, Rosner B, and Holmes MD. Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol 23, 1370–1378, 2005.
   PubMed Web of Science ®Google Scholar
• Rock CL, Flatt SW, Newman V, Caan BJ, Haan MN, et al.: Factors associated with weight gain in women after diagnosis of breast cancer. Women's Healthy Eating and Living Study Group. J Am Diet Assoc 99, 1212–1221, 1999.
   PubMed Web of Science ®Google Scholar
• Rooney M and Wald A: Interventions for the management of weight and body composition changes in women with breast cancer. Clin J Oncol Nurs 11, 41–52, 2007.
   PubMedGoogle Scholar
• Heideman WH, Russell NS, Gundy C, Rookus MA, and Voskuil DW: The frequency, magnitude and timing of post-diagnosis body weight gain in Dutch breast cancer survivors. Eur J Cancer 45, 119–126, 2009.
   PubMed Web of Science ®Google Scholar
• Schwartz AL: Exercise and weight gain in breast cancer patients receiving chemotherapy. Cancer Pract 8, 231–237, 2000.
   PubMedGoogle Scholar
• Camoriano JK, Loprinzi CL, Ingle JN, Therneau TM, Krook JE, et al.: Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer. J Clin Oncol 8, 1327–1334, 1990.
   PubMed Web of Science ®Google Scholar
• Demark-Wahnefried W, Winer EP, and Rimer BK: Why women gain weight with adjuvant chemotherapy for breast cancer. J Clin Oncol 11, 1418–1429, 1993.
   PubMed Web of Science ®Google Scholar
• McTiernan A: Obesity and cancer: the risks, science, and potential management strategies. Oncology (Williston Park) 19, 871–881; discussion, 881–872, 885–876, 2005.
   PubMed Web of Science ®Google Scholar
• Irwin ML, McTiernan A, Baumgartner RN, Baumgartner KB, Bernstein L, et al.: Changes in body fat and weight after a breast cancer diagnosis: influence of demographic, prognostic, and lifestyle factors. J Clin Oncol 23, 774–782, 2005.
   PubMed Web of Science ®Google Scholar
• Tormey C: Adjuvant systemic therapy in postoperative node-positive patients with breast carcinoma: the CALGB trial and the ECOG premenopausal trial. Recent Results Cancer Res 96, 155–165, 1984.
   PubMedGoogle Scholar
• Bonadonna G, Valagussa P, Rossi A, Tancini G, Brambilla C, et al.: Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res Treat 5, 95–115, 1985.
   PubMed Web of Science ®Google Scholar
• Rose DP and Davis TE: Ovarian function in patients receiving adjuvant chemotherapy for breast cancer. Lancet 1(8023), :1174–1176, 1977.
   PubMed Web of Science ®Google Scholar
• Heasman KZ, Sutherland HJ, Campbell JA, Elhakim T, and Boyd NF: Weight gain during adjuvant chemotherapy for breast cancer. Breast Cancer Res Treat 5, 195–200, 1985.
   PubMed Web of Science ®Google Scholar
• Knobf MK: Weight gain and adjuvant chemotherapy. Oncol Nurs Forum 12, 13, 1985.
   PubMedGoogle Scholar
• Bines J, Dienstmann R, Obadia RM, Branco LG, Quintella DC, et al.: Activity of megestrol acetate in postmenopausal women with advanced breast cancer after nonsteroidal aromatase inhibitor failure: a phase II trial. Ann Oncol 25, 831–836, 2014.
   PubMed Web of Science ®Google Scholar
• Buzdar AU, Jones SE, Vogel CL, Wolter J, Plourde P, et al.: A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group. Cancer 79, 730–739, 1997.
   Google Scholar
• Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, et al.: Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16, 453–461, 1998.
   PubMed Web of Science ®Google Scholar
• Dal Maso L, Zucchetto A, Talamini R, Serraino D, Stocco CF, et al.: Effect of obesity and other lifestyle factors on mortality in women with breast cancer. Int J Cancer 123, 2188–2194, 2008.
   PubMed Web of Science ®Google Scholar
• Rock CL and Demark-Wahnefried W: Nutrition and survival after the diagnosis of breast cancer: a review of the evidence. J Clin Oncol 20, 3302–3316, 2002.
   PubMed Web of Science ®Google Scholar
• Ryu SY, Kim CB, Nam CM, Park JK, Kim KS, et al.: Is body mass index the prognostic factor in breast cancer?: a meta-analysis. J Korean Med Sci 16, 610–614, 2001.
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Aiello E, and McTiernan A: Weight loss in breast cancer patient management. J Clin Oncol 20, 1128–1143, 2002.
   PubMed Web of Science ®Google Scholar
• Lahmann PH, Hoffmann K, Allen N, van Gils CH, Khaw KT, et al.: Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer And Nutrition (EPIC). Int J Cancer 111, 762–771, 2004.
   PubMed Web of Science ®Google Scholar
• Weiderpass E, Braaten T, Magnusson C, Kumle M, Vainio H, et al.: A prospective study of body size in different periods of life and risk of premenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 13, 1121–1127, 2004.
   PubMed Web of Science ®Google Scholar
• Stephenson GD and Rose DP: Breast cancer and obesity: an update. Nutr Cancer 45, 1–16, 2003.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA and Ferrannini E: Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14, 173–194, 1991.
   PubMed Web of Science ®Google Scholar
• Pasanisi P, Berrino F, De Petris M, Venturelli E, Mastroianni A, et al.: Metabolic syndrome as a prognostic factor for breast cancer recurrences. Int J Cancer 119, 236–238, 2006.
   Google Scholar
• Muti P, Quattrin T, Grant BJ, Krogh V, Micheli A, et al.: Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiol Biomarkers Prev 11, 1361–1368, 2002.
   PubMed Web of Science ®Google Scholar
• Schairer C, Hill D, Sturgeon SR, Fears T, Pollak M, et al.: Serum concentrations of IGF-I, IGFBP-3 and c-peptide and risk of hyperplasia and cancer of the breast in postmenopausal women. Int J Cancer 108, 773–779, 2004.
   Web of Science ®Google Scholar
• Michels KB, Solomon CG, Hu FB, Rosner BA, Hankinson SE, et al.: Type 2 diabetes and subsequent incidence of breast cancer in the Nurses’ Health Study. Diabetes Care 26, 1752–1758, 2003.
   PubMed Web of Science ®Google Scholar
• Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, et al.: Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 20, 42–51, 2002.
   PubMed Web of Science ®Google Scholar
• Healy LA, Ryan AM, Carroll P, Ennis D, Crowley V, et al.: Metabolic syndrome, central obesity and insulin resistance are associated with adverse pathological features in postmenopausal breast cancer. Clin Oncol (R Coll Radiol) 22, 281–288, 2010.
   PubMed Web of Science ®Google Scholar
• Mathieu MC, Clark GM, Allred DC, Goldfine ID, and Vigneri R: Insulin receptor expression and clinical outcome in node-negative breast cancer. Proc Assoc Am Physicians 109, 565–571, 1997.
   PubMedGoogle Scholar
• Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, et al.: Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 19, 3278–3288, 1999.
   PubMed Web of Science ®Google Scholar
• Yamaguchi Y, Flier JS, Yokota A, Benecke H, Backer JM, et al.: Functional properties of two naturally occurring isoforms of the human insulin receptor in Chinese hamster ovary cells. Endocrinology 129, 2058–2066, 1991.
   PubMed Web of Science ®Google Scholar
• Vella V, Pandini G, Sciacca L, Mineo R, Vigneri R, et al.: A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. J Clin Endocrinol Metab 87, 245–254, 2002.
   PubMed Web of Science ®Google Scholar
• Girnita L, Girnita A, Brodin B, Xie Y, Nilsson G, et al.: Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: functional impact. Cancer Res 60, 5278–5283, 2000.
   PubMed Web of Science ®Google Scholar
• Papa V and Belfiore A: Insulin receptors in breast cancer: biological and clinical role. J Endocrinol Invest 19, 324–333, 1996.
   PubMed Web of Science ®Google Scholar
• Patel NM, Nozaki S, Shortle NH, Bhat-Nakshatri P, Newton TR, et al.: Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide. Oncogene 19, 4159–4169, 2000.
   PubMed Web of Science ®Google Scholar
• Funahashi T, Nakamura T, Shimomura I, Maeda K, Kuriyama H, et al.: Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity. Intern Med 38, 202–206, 1999.
   PubMed Web of Science ®Google Scholar
• Rajala MW and Scherer PE: Minireview: The adipocyte–at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 144, 3765–3773, 2003.
   PubMed Web of Science ®Google Scholar
• Railo MJ, von Smitten K, and Pekonen F: The prognostic value of insulin-like growth factor-I in breast cancer patients. Results of a follow-up study on 126 patients. Eur J Cancer 30A, 307–311, 1994.
   PubMed Web of Science ®Google Scholar
• Happerfield LC, Miles DW, Barnes DM, Thomsen LL, Smith P, et al.: The localization of the insulin-like growth factor receptor 1 (IGFR-1) in benign and malignant breast tissue. J Pathol 183, 412–417, 1997.
   PubMed Web of Science ®Google Scholar
• Foekens JA, Portengen H, van Putten WL, Trapman AM, Reubi JC, et al.: Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res 49(24, Pt. 1), 7002–7009, 1989.
   PubMed Web of Science ®Google Scholar
• Bhatavdekar JM, Patel DD, Karelia NH, Vora HH, Ghosh N, et al.: Tumor markers in patients with advanced breast cancer as prognosticators: a preliminary study. Breast Cancer Res Treat 30, 293–297, 1994.
   PubMed Web of Science ®Google Scholar
• Verheus M, Peeters PH, Rinaldi S, Dossus L, Biessy C, et al.: Serum C-peptide levels and breast cancer risk: results from the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 119, 659–667, 2006.
   PubMed Web of Science ®Google Scholar
• Redig AJ and Munshi HG: Care of the cancer survivor: metabolic syndrome after hormone-modifying therapy. Am J Med 123, e81–86, 2010.
   Google Scholar
• Meigs JB, Wilson PW, Fox CS, Vasan RS, Nathan DM, et al.: Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab 91, 2906–2912, 2006.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Angulo AM and Meric-Bernstam F: Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res 16, 1695–1700, 2010.
   PubMed Web of Science ®Google Scholar
• Maiti B, Kundranda MN, Spiro TP, and Daw HA: The association of metabolic syndrome with triple-negative breast cancer. Breast Cancer Res Treat 121, 479–483, 2010.
   PubMed Web of Science ®Google Scholar
• Holmes MD, Chen WY, Feskanich D, Kroenke CH, and Colditz GA: Physical activity and survival after breast cancer diagnosis. JAMA 293, 2479–2486, 2005.
   PubMed Web of Science ®Google Scholar
• Pinto BM and Maruyama NC: Exercise in the rehabilitation of breast cancer survivors. Psychooncology 8, 191–206, 1999.
   PubMed Web of Science ®Google Scholar
• Bianchini F, Kaaks R, and Vainio H: Weight control and physical activity in cancer prevention. Obes Rev 3, 5–8, 2002.
   PubMedGoogle Scholar
• Kramer JA, Curran D, Piccart M, de Haes JC, Bruning P, et al.: Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer. Eur J Cancer 36, 1498–1506, 2000.
   PubMed Web of Science ®Google Scholar
• Kirshbaum MN: A review of the benefits of whole body exercise during and after treatment for breast cancer. J Clin Nurs 16, 104–121, 2007.
   PubMed Web of Science ®Google Scholar
• Ohira T, Schmitz KH, Ahmed RL, and Yee D: Effects of weight training on quality of life in recent breast cancer survivors: the Weight Training for Breast Cancer Survivors (WTBS) study. Cancer 106, 2076–2083, 2006.
   PubMed Web of Science ®Google Scholar
• De Backer IC, Schep G, Backx FJ, Vreugdenhil G, and Kuipers H: Resistance training in cancer survivors: a systematic review. Int J Sports Med 30, 703–712, 2009.
   PubMed Web of Science ®Google Scholar
• Henriksen EJ: Exercise training and the antioxidant alpha-lipoic acid in the treatment of insulin resistance and type 2 diabetes. Free Radic Biol Med 40, 3–12, 2006.
   PubMed Web of Science ®Google Scholar
• Perez-Martin A, Raynaud E, and Mercier J: Insulin resistance and associated metabolic abnormalities in muscle: effects of exercise. Obes Rev 2, 47–59, 2001.
   PubMedGoogle Scholar
• Goulet ED, Melancon MO, Aubertin-Leheudre M, and Dionne IJ: Aerobic training improves insulin sensitivity 72-120 h after the last exercise session in younger but not in older women. Eur J Appl Physiol 95, 146–152, 2005.
   PubMed Web of Science ®Google Scholar
• Christ-Roberts CY, Pratipanawatr T, Pratipanawatr W, Berria R, Belfort R, et al.: Exercise training increases glycogen synthase activity and GLUT4 expression but not insulin signaling in overweight nondiabetic and type 2 diabetic subjects. Metabolism 53, 1233–1242, 2004.
   PubMed Web of Science ®Google Scholar
• Oh EG, Chu SH, Bang SY, Lee MK, Kim SH, et al.: Effects of a therapeutic lifestyle modification program on inflammatory chemokines and insulin resistance in subjects with metabolic syndrome. Biol Res Nurs 13, 182–188, 2011.
   PubMed Web of Science ®Google Scholar
• Chen CN, Chuang LM, and Wu YT: Clinical measures of physical fitness predict insulin resistance in people at risk for diabetes. Phys Ther88, 1355–1364, 2008.
   PubMed Web of Science ®Google Scholar
• Schmitz KH, Ahmed RL, Hannan PJ, and Yee D: Safety and efficacy of weight training in recent breast cancer survivors to alter body composition, insulin, and insulin-like growth factor axis proteins. Cancer Epidemiol Biomarkers Prev 14, 1672–1680, 2005.
   PubMed Web of Science ®Google Scholar
• Fairey AS, Courneya KS, Field CJ, Bell GJ, Jones LW, et al.: Effects of exercise training on fasting insulin, insulin resistance, insulin-like growth factors, and insulin-like growth factor binding proteins in postmenopausal breast cancer survivors: a randomized controlled trial. Cancer Epidemiol Biomarkers Prev 12, 721–727, 2003.
   PubMed Web of Science ®Google Scholar
• Ligibel JA, Campbell N, Partridge A, Chen WY, Salinardi T, et al.: Impact of a mixed strength and endurance exercise intervention on insulin levels in breast cancer survivors. J Clin Oncol 26, 907–912, 2008.
   PubMed Web of Science ®Google Scholar
• Arikawa AY, Kurzer MS, Thomas W, and Schmitz KH: No effect of exercise on insulin-like growth factor-I, insulin, and glucose in young women participating in a 16-week randomized controlled trial. Cancer Epidemiol Biomarkers Prev 19, 2987–2990, 2010.
   PubMed Web of Science ®Google Scholar
• Battaglini C, Bottaro M, Dennehy C, Rae L, Shields E, et al.: The effects of an individualized exercise intervention on body composition in breast cancer patients undergoing treatment. Sao Paulo Med J 125, 22–28, 2007.
   PubMed Web of Science ®Google Scholar
• Shang J, Wenzel J, Krumm S, Griffith K, and Stewart K: Who will drop out and who will drop in: exercise adherence in a randomized clinical trial among patients receiving active cancer treatment. Cancer Nurs 35, 312–322, 2012.
   PubMed Web of Science ®Google Scholar
• Pickett M, Mock V, Ropka ME, Cameron L, Coleman M, et al.: Adherence to moderate-intensity exercise during breast cancer therapy. Cancer Pract 10, 284–292, 2002.
   PubMedGoogle Scholar
• Oldervoll LM, Loge JH, Paltiel H, Asp MB, Vidvei U, et al.: The effect of a physical exercise program in palliative care: A phase II study. J Pain Symptom Manage 31, 421–430, 2006.
   PubMed Web of Science ®Google Scholar
• Rajarajeswaran P and Vishnupriya R: Exercise in cancer. Indian J Med Paediatr Oncol 30, 61–70, 2009.
   PubMedGoogle Scholar
• Segal R, Evans W, Johnson D, Smith J, Colletta S, et al.: Structured exercise improves physical functioning in women with stages I and II breast cancer: results of a randomized controlled trial. J Clin Oncol 19, 657–665, 2001.
   PubMed Web of Science ®Google Scholar